Kornimate/medical-research-clean huggingface dataset:
evaluate the clinical effectiveness of regenkit platelet-rich plasma (prp) in androgenetic alopecia treatment

Conditions: Androgenetic Alopecia

Summary: platelet rich plasma (prp) therapy is a novel therapeutic modality that has seen broad applications for a number of medical indications including those in orthopedics, dentistry, and dermatology. in dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. more recently, anecdotal reports have suggested some efficacy in the treatment of hair loss, but to the best of our knowledge, there has been only one published case series documenting its use for this indication.

this study was designed to better assess the efficacy of prp in hair loss, we therefore propose to study interval intralesional prp injections for patients with androgenetic alopecia (aga). androgenetic alopecia is the most common form of hair loss world-wide. although there are currently numerous treatment options for this indication including minoxidil, 5-alpha reductase inhibitors and follicular unit transplant, many of the medical treatment options have undesirable side effects, particularly in women of child bearing age. these well-documented adverse reactions include impotency, hypertrichosis, and birth defects.

Eligibility criteria:
inclusion criteria: * men and women, age 18-60 with aga * completed informed consent form * ludwig stage 1-2 for women * norwood hamilton stage 3 to 5 for men exclusion criteria: * pregnancy or breastfeeding * younger than 18 years * uses of minoxidil and/or 5-alpha reductase inhibitors (such as finasteride or dutasteride) within 3 months of enrolling in the study * history of hair transplantation * use of any cosmetic product aimed at improving or correcting the signs of hair loss within 2 weeks prior to screening * facial cancer (squamous and basal cell carcinoma, melanoma) * hereditary or acquired hematologic/coagulation disorders such as: platelet dysfunction syndrome, critical thrombocytopenia, hypofibrinogenemia, impaired coagulation, drepanocytosis (sickle cell anemia). * hemodynamic instability * acute infection * auto-immune disease such as hashimoto, rheumatoid arthritis, or lupus (exception: vitiligo and alopecia areata) * malignancy with or without metastatic disease * chemotherapy * dermatological diseases affecting the face (e.g. porphyria) * anticoagulant therapy * patients taking aspirin or other nsaids (nonsteroidal anti-inflammatory drugs) such as nurofen, voltaren, diclofenac or naproxen can participate, provided medication is interrupted 7 days before beginning of the treatment * patients taking vitamin e supplements can participate, provided medication is interrupted 14 days before beginning of the treatment

Keywords: platelet rich plasma hair loss
mucus dehydration and evolution of chronic obstructive pulmonary disease (copd) lung disease

Conditions: Chronic Obstructive Pulmonary Disease; Chronic Bronchitis

Summary: the purpose of this research is to understand the properties of mucus in persons with copd, specifically chronic bronchitis. we hypothesize that those with chronic bronchitis have dehydrated mucus, and thus have a harder time coughing it out of their lungs. this leads to a greater vulnerability for lung infection, inflammation and airflow obstruction. ultimately, our goal is to understand how mucus dehydration contributes to the progression of copd/chronic bronchitis so that better therapies and interventions can be developed for future generations.

specific aim i directly tests the hypothesis that mucus clearance is impaired due to mucus dehydration. it measures 1) copd mucociliary and cough clearance 2) mucus hydration 3) the concentrations of the dominant regulators of airway hydration and 4) the consequences of mucus dehydration on mucus biophysical properties and bacterial infection. specific aim ii tests the hypothesis that copd acute exacerbations are associated with failures of mucus clearance. measurements will be similar to that of specific aim i, but conducted during periods of baseline health, acute exacerbation and recovery. specific aim iii tests whether airway surface hydration with 7% hypertonic saline will restore clearance in the basal state and during a copd acute exacerbation. copd subjects will be exposed to inhaled hypertonic saline during periods of baseline health and acute exacerbation. acute efficacy via measures of mucus clearance and spirometry will studied.

Eligibility criteria:
inclusion criteria: * history of copd/chronic bronchitis defined as having a productive cough for three months of the year for at least two successive years * greater than or equal to a 10 pack year cigarette smoking history * ability to perform spirometry exclusion criteria: * unstable lung disease * allergy to study medications * radiation exposure within past year exceeding federal regulation limits

Keywords: mucus copd chronic bronchitis
frailty assessment and treatment strategies in the elderly at risk of functional decline in the community

Conditions: Frail Elderly Syndrome

Summary: this study aims to design a patient -centered program to prevent or delay frailty , functional decline and adverse events, and evaluates the effectiveness of the program with a randomized clinical trial.

objective: to design and evaluate the implementation and impact of a multimodal intervention focused on elderly patients living in the community in preventing or delaying frailty, functional decline and risk of institutionalization, hospitalization and death. design: study in two phases: a qualitative study to develop the intervention and a randomized clinical trial with parallel arms and control group. intervention: participants in the control group will receive the usual standard care and regular referrals. patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment (cga). then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment, along with medication review, aerobics exercise plan and memory workshops following the model adapted in phase i. after 3 and 18 months, measures of functional and cognitive performance, quality of life, frailty, adverse outcomes (institutionalization, hospitalization, death) and health care costs will be collected.

Eligibility criteria:
inclusion criteria: * positive screen in the accumulation of deficits electronic frailty index * positive screen with gerontopole screening tool and/or risc tool exclusion criteria: * living in an institution * advanced conditions with short life expectancy * severe disability * severe dementia

Keywords: frail elderly clinical trial
cohort of patients with rare iron overloads excluding c282y homozygosity

Conditions: Rare Iron Overlaods

Summary: the study explores the hepcidin deficiency causes of rare iron overload (excluding c282y homozygosity), and aim to characterize this iron overload in term of clinical, biological, genetic and functional spacificities.

chronic iron overload are responsible for morbidity and mortality. there are many causes, genetic and acquired. hepcidin deficiency related to genetic desease is one of them. this study concerns specifically this cause, and seeks to characterize these iron overloads on clinical, biological, genetic and functional point of view. a significant number of patients with chronic iron overload, present a phenotype of hepcidin deficiency. this profile is characterized by an elevated plasma iron increased serum transferrin saturation, a transferrin saturation, and a parenchyma distribution of iron overload. these diseases either remains unexplained or are associated with mutations in the gene involved in iron metablism regulation. the main objective of this study is to characterize these iron overloads with phenotype of hepcidin deficiency not related to homozygosity c282y (clinical, biological and genetic).

Eligibility criteria:
inclusion criteria: * biological profile suggestive of hepcidin deficiency: * increase of transferrin saturation coefficient (\> 50 %) verified on at least 2 times, and calculated from the transferrinemia. * proved hepatic iron overload: by the dosage of the iron hepatic concentration either on block hepatic biopsic, or by mri according to the method of quantification of the iron validated overload (by adopting a threshold of 100 µmol /g) * patient's written consent for examination of genetic characteristics for diagnosis and collection development for genetic and not genetic research within the framework of an abnormality of the iron metabolism * patient written inform consent. exclusion criteria: * hfe hemochromatosis: homozygosity c282y/c282y * treatment with iterative phlebotomy * hematologic diseases with dyserythropoiesis and/or repeated transfusions * haptoglobin low, below normal directing towards the diagnosis of chronic hemolysis, myelodysplasia * prolonged oral or parenteral iron supplementation * current or past excessive regular drinking * patient minor or under legal protection measure

Keywords: hepcidin deficiency genetic except c282y homozygosity
quality of life 1y and 2 y after vv-ecmo for covid-19

Conditions: COVID-19 Acute Respiratory Distress Syndrome; Extracorporeal Membrane Oxygenation Complication; Quality of Life; Death

Summary: this study aims to investigate the quality of life and the outcome after veno-venous extracoporeal membrane oxygenation (ecmo) support fir severe acute respiratory syndrome (ards) in covid-19 patients.

the investigators follow our covid-19 patients supported by ecmo, we make phone calls or real-life visits to pthe patients to score the quality of life, by using the sf-36. the sf-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality , social functioning , role emotional , and mental health. the participants are contacted 3 months, 6months, 1year and 2 years after the ecmo support started for evaluation of the sf-36.

Eligibility criteria:
inclusion criteria: * patients with pcr-confirmed covid-19 infection and * acute respiratory distress syndrome who require veno-venous ecmo therapy. exclusion criteria: * none

Keywords: ecmo covid-19 quality of life
correlation of fc gamma riiia receptor response in patients with waldenstrom's macroglobulinemia

Conditions: Waldenstrom's Macroglobulinemia

Summary: the purpose of this study is to determine if the type of fc gamma riiia receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.

* a medical data collection survey sheet will be filled out by the patient or doctor with medical information pertaining to how the patient responded to rituximab and other monoclonal antibodies for use in this study. * blood work will be performed to analyze the blood by molecular technology to find the kind of fc gamna riiia receptor the patient possess and correlate these findings with the outcome of treatment with rituximab or other monoclonal antibodies.

Eligibility criteria:
inclusion criteria: * patients treated with rituximab or other monoclonal antibodies for waldenstrom's macroglobulinemia

Keywords: monoclonal antibody fc gamma riii receptor expression rituximab
vertebral bone quality and prediction of screw loosening in spine fusion

Conditions: Spine Fusion for Degenerative Spine Disease

Summary: finding a way to use vertebral ct scan will help to predict screw loosing risk in spinal fusion for degenerative spine disease. patients who will undergo at least two spine fusion levels for degenerative spine disease will be enrolled in. before surgery, patients will undergo a spinal qct scan with a calibrated phantom. the calibrated bone density, at bone-implant interface, will be assessed using dual energy ct scan immediately after surgery, and six months later. the primary outcomes will be the difference between the two values of the bone implant interface. the difference between density values will be correlated to the pre-op bone density value.

screw loosening is a real problem in degenerative spine surgery because of the morbidity of secondary surgery sometimes needed for elderly patients. today, there is no real possibility to know before surgery if cemented screws are needed or not. the use of cemented screws has its morbidity. in fact, bone densitometry is not a good exam to predict the bone quality in degenerative spine because of the arthritis. t-score in degenerative spine can be overestimated. the goal of our study is analyze the bone-implant interface after spine fusion using dual-energy ct scan technology which can provide pictures without artifact compared to standard ct scan. this is a prospective observational monocentric study. patients over 18 years old and have undergone at least two primary spine fusion levels will be enrolled. the exclusion criteria are the use of cemented screws, secondary surgery and neurodegenerative disease. the primary outcome will be the change in the bone-implant interface at six months post-surgery compared to the interface after surgery. the change will be assessed by calibrated dual ct scan. the interface bone density will be assessed using calibrated scans, and correlate to the true vertebral bone density measured before surgery with a qct. we hope that this study can provide a simple and reproducible help for surgeons to choose between uncommented and cemented screws for their spine fusions surgeries.

Eligibility criteria:
inclusion criteria: * more than 18 years old * needed a minimum 2 levels spinal fusion * agreed protocol exclusion criteria: * cimented pedicular screws * secondary surgery * neurodegenerative disease

Keywords: degenerative spine disease screw loosening quantitative ct scan vertebral bone density
a study of two different schedules of xeloda (capecitabine) as first line therapy in patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this 2-arm study evaluated the efficacy and safety of 2 different treatment schedules of oral xeloda with intravenous (iv) eloxatin (oxaliplatin) and iv bevacizumab (avastin) as a first-line treatment in patients with locally advanced or metastatic colorectal cancer. patients were randomized to receive either: 1) xeloda 850 mg/m\^2 orally twice a day (po bid) on days 1-14, oxaliplatin 130 mg/m\^2 iv on day 1, and avastin 7.5 mg/kg iv on day 1 of each 3-week cycle; or 2) xeloda 1500 mg/m\^2 po bid on days 1-7, oxaliplatin 85 mg/m\^2 iv on day 1 and avastin 5 mg/kg iv on day 1 of each 2-week cycle. the anticipated time on study treatment was 1-2 years, and the target sample size was 100-500 individuals.


Eligibility criteria:
inclusion criteria: * metastatic or inoperable locally advanced colorectal cancer * \>=1 measurable target lesion exclusion criteria: * previous systemic therapy for advanced or metastatic disease * previous treatment with bevacizumab
effect of muscular exercise on cough reflex

Conditions: Cough

Summary: the hypothesis is that the cough reflex induced by capsaicin is inhibited during exercise. the purpose of this study is to determine if a short muscular exercise inhibits the cough reflex induced by capsaicin inhalation.

cough is an important reflex of defense of airways. it is also one of the more frequent symptoms during respiratory diseases. chronic cough can be a disabling condition, apparently idiopathic or associated to pathology such as asthma, sinusitis with posterior discharge or gastroesophageal reflux. factors susceptible to provoke or increase cough are well known, but inhibiting factors are much less known. muscular exercise is thought to influence respiratory reflexes in a considerable and complicated way. for example, a bronchodilation is observed in healthy or asthmatic individuals, but recovery period frequently triggers asthma attacks. effects of exercise on cough reflex are much less known. this study aims to determine the influence of muscular exercise on cough reflex in children and healthy adults. highlighting the inhibition of cough reflex by exercise can have a significant effect on chronic cough patient care. there is actually no symptomatic treatment really effective without side effects.

Eligibility criteria:
inclusion criteria: * obtaining of informed consent (or informed consent of parents or persons with parental authority) * affiliation to social security * negative answer to all 12 questions of medical questionnaire for child or to all 11 questions of medical questionnaire for adult * normal cardio-respiratory examination * normal electrocardiogram * without spirometry obstructive syndrome (fev1 \> 70% of predicted value and fev1/fvc \>70%) exclusion criteria: * refusal or impossibility of obtaining informed consent of person or of persons with parental authority)
a safety study for previously treated vatiquinone (ptc743) participants with inherited mitochondrial disease

Conditions: Inherited Mitochondrial Disease

Summary: the primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a ptc/bioelectron sponsored (previously edison) clinical study or treatment plan. the study will continue until vatiquinone becomes commercially available or the program is terminated.


Eligibility criteria:
inclusion criteria: * participants with inherited mitochondrial disease including leigh syndrome, alpers syndrome, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (melas), myoclonic epilepsy with ragged-red fibers (merrf), pontocerebellar hypoplasia type 6 (pch6), or other mitochondrial disease who participated in a previous vatiquinone clinical study or treatment plan. * women of childbearing potential must have a negative pregnancy test at screening/baseline and agree to abstinence or the use of at least 1 of the highly effective forms of contraception as specified in the protocol (with a failure rate of \<1% per year when used consistently and correctly). highly effective contraception or abstinence must be continued for the duration of the study, and for up to 30 days after the last dose of study drug. * fertile men who are sexually active with women of childbearing potential and who have not had a vasectomy, must agree to use a barrier method of birth control during the study and for up to 30 days after the last dose of study drug. exclusion criteria: * current participation in any other interventional study. * pregnancy or breast feeding.

Keywords: leigh syndrome alpers syndrome mitochondrial encephalomyopathy melas merrf pch6 refractory epilepsy
blood flow restriction following acl reconstruction

Conditions: Anterior Cruciate Ligament Rupture

Summary: the main objective is to determine the impact of blood flow restriction (bfr) therapy, in comparison to a standard rehabilitation protocol, on preventing atrophy, improving quadriceps strength and improving functional outcomes of patients recovering from acl reconstruction. the investigators hypothesize that patients undergoing bfr therapy after acl reconstruction surgery will have better functional outcomes than those undergoing normal rehabilitation without bfr therapy.

recovery from anterior cruciate ligament (acl) reconstruction involves early physical therapy to promote muscular development. traditional training regimens are based on the concept that muscle growth is induced with high resistance exercises of at least 65-70% of 1-repetition maximum. achieving a high resistance level can be challenging in the early post-surgical patient who may be limited by pain, muscle atrophy, diminished proprioception, and psychological factors. increasing evidence has suggested that blood flow restriction (bfr) in resistance training, while transmitting a decreased load (25-50% of 1-repetition maximum) across the surgical site, may provide an additional benefit of inducing muscular development similar to that of high intensity exercises . augmenting exercises with bfr involves an external pressure cuff applied to the proximal portion of the extremity, which is inflated to a pressure that restricts venous outflow while allowing arterial inflow to continue. this creates a physiologic environment for the patient to gain the hypertrophic effect of high resistance training, though at a lower and safer intensity. studies suggest that bfr stimulates muscular development through an increase in metabolic stress, muscle fiber recruitment, cell swelling, and protein synthesis.

Eligibility criteria:
inclusion criteria: 1. age 13-35 years at the time of surgery 2. anterior cruciate ligament (acl) reconstruction 3. using a physical therapy center with blood flow restriction capabilities. exclusion criteria: 1. concomitant ligament reconstruction 2. concurrent procedures that require delayed weight bearing (ie: high tibial osteotomy (hto), multi-ligament reconstruction, microfracture, etc) 3. history of deep vein thrombosis (dvt)/pulmonary embolism (pe) 4. immunocompromising conditions (ie: rheumatoid arthritis, chronic steroid use, etc.) 5. history of coagulation disorders or current use of anticoagulants 6. completion of physical therapy at a location not affiliated with the study 7. pregnancy

Keywords: bfr acl rehabilitation
efficacy of nnc109-0012 in subjects with active rheumatoid arthritis

Conditions: Inflammation; Rheumatoid Arthritis

Summary: this trial is conducted in europe. the aim of this trial is to evaluate the change in disease activity following 12 weekly s.c. (under the skin) doses of nnc109-0012 compared to placebo in subjects with active rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * czech republic: age between 18 - 65 years (both inclusive) * a diagnosis of ra made at least 3 months prior to trial start * active ra * methotrexate treatment (between 7.5 mg and 25 mg/week, both inclusive) for at least 12 weeks with a stable dose for at least 4 weeks prior to trial start * female subjects must be willing to avoid pregnancy and breast feeding throughout this trial at least until 15 weeks following the last dose of trial medication * male subjects with partners of childbearing potential must be willing to use a highly effective contraception throughout trial incl. a 15 week follow up periode exclusion criteria: * known or suspected allergy to trial product or related products * body mass index (bmi) lower than 18.5 or higher than 35.0 kg/m\^2 * subjects with chronic inflammatory autoimmune disease other than ra (except secondary sjögren's syndrome or stable hypothyroidism)
effectiveness and possible complications of core needle biopsy of orbital tumors

Conditions: Orbial Mass Lesion

Summary: core needle biopsy of orbital mass lesions with a semiautomated needles is a safe procedure that provides a sufficient amount of tissue material for standard histological and immunohistochemical analysis and can be an alternative or supplement to fine needle aspiration biopsy


Eligibility criteria:
inclusion criteria: * unresectable mass lesions with diffuse involvement of the orbit or the tumors with infiltrative growth and indistinct borders which needed to have morphologic verification exclusion criteria: * an anti-coagulant therapy at the time of biopsy, * bleeding diathesis, * suspected hypervascular lesions, * orbital roof destruction with a tumor, * apical location of the tumor

Keywords: orbit; tumor; core biopsy